Autopsy report · NCT04593329

Efficacy and Safety of Tiradentes Association in the Treatment of Acute Pain

“Strategy review”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

EMS

Sponsor type

Industry

Conditions

Acute Pain

Interventions

TIRADENTES ASSOCIATION; DIPYRONE; TRAMADOL; TIRADENTES ASSOCIATION PLACEBO; DIPYRONE PLACEBO; TRAMADOL PLACEBO

Participants

0

Trials that died the same way

• Choroidal Changes Post Short Term Exposure To Virtual Reality Devices
  “Strategy change” (71% match in meaning)
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
  “Change in strategy” (70% match in meaning)
• CD8 Minibody Repeatability Study
  “Strategic decision” (67% match in meaning)
• A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
  “Strategic considerations” (66% match in meaning)
• A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002
  “Business strategy” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.